|Bid||82.00 x 200|
|Ask||86.00 x 100|
|Day's Range||82.91 - 83.45|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.31|
|Dividend & Yield||2.72 (3.27%)|
|1y Target Est||N/A|
Despite the success of new products, GlaxoSmithKline plc (GSK) believes that its overall performance has been weaker than it would have liked.
After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneering cancer treatment. As manufacturer of the virus-based gene delivery system central to the Novartis therapy, which re-engineers a patient's immune cells to attack cancer, the small British company will receive a modest slice of the revenue once the new drug is approved. The payout will hardly make a dent in returns for Swiss drugs giant Novartis, but the 65-75 million pounds ($83-96 million) a year that Jefferies analysts predict Oxford Bio will earn should put it on a path to sustainable profitability.
Incyte's Jakafi is the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera.